BioMarin Pharmaceutical Inc. (0HNC.L)
USD 62.08
(-1.62%)
USD 62.08
(-1.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 310.28 Million USD | 64.24% |
| 2022 | 267.51 Million USD | 232.14% |
| 2021 | 48.02 Million USD | 920.96% |
| 2020 | -5.85 Million USD | 73.7% |
| 2019 | 33.94 Million USD | 77.81% |
| 2018 | -3.54 Million USD | -39.82% |
| 2017 | 94.75 Million USD | 62.74% |
| 2016 | -705.52 Million USD | 33.02% |
| 2015 | -110.7 Million USD | -108.54% |
| 2014 | -49.95 Million USD | -15.97% |
| 2013 | -137.35 Million USD | -29.23% |
| 2012 | -79.83 Million USD | -187.67% |
| 2011 | -172 Thousand USD | -495.91% |
| 2010 | 17.06 Million USD | -63.03% |
| 2009 | 35.63 Million USD | -59.71% |
| 2008 | 67.44 Million USD | 202.4% |
| 2007 | -57.28 Million USD | -316.18% |
| 2006 | -14.88 Million USD | 76.51% |
| 2005 | -54.46 Million USD | -54.99% |
| 2004 | -134.63 Million USD | 26.72% |
| 2003 | -66.36 Million USD | -24.3% |
| 2002 | -59.12 Million USD | -77.13% |
| 2001 | -40.63 Million USD | -18.1% |
| 2000 | -29.94 Million USD | 4.85% |
| 1999 | -20.38 Million USD | -51.72% |
| 1998 | -12.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 129.92 Million USD | 18.86% |
| 2024 Q1 | 109.21 Million USD | 160.96% |
| 2024 Q3 | 113.89 Billion USD | -3.55% |
| 2023 Q4 | 41.08 Million USD | -15.33% |
| 2023 FY | - USD | 64.24% |
| 2023 Q2 | 82.19 Million USD | -5.41% |
| 2023 Q3 | 48.51 Million USD | -40.97% |
| 2023 Q1 | 86.88 Million USD | 718.07% |
| 2022 FY | - USD | 232.14% |
| 2022 Q1 | 57.33 Million USD | 256.05% |
| 2022 Q2 | 63.98 Million USD | 11.59% |
| 2022 Q4 | 10.62 Million USD | -61.49% |
| 2022 Q3 | 27.57 Million USD | -56.9% |
| 2021 FY | - USD | 920.96% |
| 2021 Q3 | -15.45 Million USD | -134.18% |
| 2021 Q2 | 45.2 Million USD | -17.83% |
| 2021 Q1 | 55.01 Million USD | 427.55% |
| 2021 Q4 | -36.74 Million USD | -137.8% |
| 2020 Q1 | 64.44 Million USD | 1455.61% |
| 2020 FY | - USD | 73.7% |
| 2020 Q2 | -19.31 Million USD | -129.97% |
| 2020 Q3 | -34.19 Million USD | -77.03% |
| 2020 Q4 | -16.79 Million USD | 50.87% |
| 2019 Q4 | 4.14 Million USD | -86.11% |
| 2019 Q1 | -26.46 Million USD | 54.98% |
| 2019 Q2 | -29.74 Million USD | -12.39% |
| 2019 FY | - USD | 77.81% |
| 2019 Q3 | 29.82 Million USD | 200.27% |
| 2018 Q4 | -58.78 Million USD | -620.3% |
| 2018 Q3 | 11.29 Million USD | 142.28% |
| 2018 Q2 | -26.72 Million USD | -2.63% |
| 2018 Q1 | -26.04 Million USD | 32.12% |
| 2018 FY | - USD | -39.82% |
| 2017 Q4 | -38.36 Million USD | -541.84% |
| 2017 Q2 | -17.3 Million USD | -498.87% |
| 2017 Q3 | -5.97 Million USD | 65.46% |
| 2017 Q1 | 4.33 Million USD | 105.78% |
| 2017 FY | - USD | 62.74% |
| 2016 Q3 | -47.17 Million USD | -280.64% |
| 2016 Q4 | -75.06 Million USD | -59.12% |
| 2016 Q2 | 26.11 Million USD | 137.94% |
| 2016 Q1 | -68.84 Million USD | -0.5% |
| 2016 FY | - USD | 33.02% |
| 2015 Q1 | -63.81 Million USD | -16.9% |
| 2015 Q4 | -68.5 Million USD | 14.05% |
| 2015 FY | - USD | -108.54% |
| 2015 Q3 | -79.69 Million USD | -39.64% |
| 2015 Q2 | -57.07 Million USD | 10.56% |
| 2014 Q2 | -14.83 Million USD | 10.4% |
| 2014 Q4 | -54.58 Million USD | -4.51% |
| 2014 FY | - USD | -15.97% |
| 2014 Q1 | -16.56 Million USD | 60.94% |
| 2014 Q3 | -52.22 Million USD | -251.96% |
| 2013 Q1 | -37.24 Million USD | -5.6% |
| 2013 Q4 | -42.39 Million USD | -0.59% |
| 2013 FY | - USD | -29.23% |
| 2013 Q3 | -42.15 Million USD | -114.09% |
| 2013 Q2 | -19.68 Million USD | 47.13% |
| 2012 Q1 | -19.76 Million USD | -67.35% |
| 2012 FY | - USD | -187.67% |
| 2012 Q4 | -35.26 Million USD | -309.78% |
| 2012 Q3 | -8.6 Million USD | 69.56% |
| 2012 Q2 | -28.26 Million USD | -43.01% |
| 2011 Q2 | 899 Thousand USD | -68.41% |
| 2011 Q1 | 2.84 Million USD | -39.49% |
| 2011 FY | - USD | -495.91% |
| 2011 Q4 | -11.81 Million USD | 4.46% |
| 2011 Q3 | -12.36 Million USD | -1475.19% |
| 2010 FY | - USD | -63.03% |
| 2010 Q1 | 3.94 Million USD | -65.58% |
| 2010 Q2 | 4.79 Million USD | 21.58% |
| 2010 Q3 | 2.36 Million USD | -50.73% |
| 2010 Q4 | 4.7 Million USD | 99.11% |
| 2009 FY | - USD | -59.71% |
| 2009 Q4 | 11.45 Million USD | 9.0% |
| 2009 Q1 | 2.3 Million USD | -95.59% |
| 2009 Q2 | 10.48 Million USD | 354.16% |
| 2009 Q3 | 10.51 Million USD | 0.28% |
| 2008 Q2 | 7.53 Million USD | 294.4% |
| 2008 FY | - USD | 202.4% |
| 2008 Q1 | 1.91 Million USD | 123.09% |
| 2008 Q4 | 52.34 Million USD | 815.42% |
| 2008 Q3 | 5.71 Million USD | -24.13% |
| 2007 Q2 | -12.5 Million USD | 20.44% |
| 2007 Q1 | -15.72 Million USD | -74.65% |
| 2007 Q4 | -8.27 Million USD | 49.56% |
| 2007 FY | - USD | -316.18% |
| 2007 Q3 | -16.4 Million USD | -31.18% |
| 2006 Q4 | -9 Million USD | -493.96% |
| 2006 Q2 | 2.43 Million USD | 147.61% |
| 2006 Q1 | -5.12 Million USD | 49.03% |
| 2006 FY | - USD | 76.51% |
| 2006 Q3 | 2.28 Million USD | -6.31% |
| 2005 Q2 | -16.36 Million USD | 25.47% |
| 2005 FY | - USD | -54.99% |
| 2005 Q4 | -10.05 Million USD | 6.46% |
| 2005 Q3 | -10.74 Million USD | 34.36% |
| 2005 Q1 | -21.96 Million USD | -23.24% |
| 2004 FY | - USD | 26.72% |
| 2004 Q2 | 21.26 Million USD | 224.48% |
| 2004 Q3 | -20.41 Million USD | -195.99% |
| 2004 Q4 | -17.82 Million USD | 12.7% |
| 2004 Q1 | -17.08 Million USD | 24.83% |
| 2003 Q1 | -18.45 Million USD | 30.68% |
| 2003 FY | - USD | -24.3% |
| 2003 Q4 | -22.72 Million USD | -28.13% |
| 2003 Q3 | -17.73 Million USD | -138.51% |
| 2003 Q2 | -7.43 Million USD | 51.08% |
| 2002 Q1 | -11.29 Million USD | 171.36% |
| 2002 Q3 | -12.66 Million USD | -23.74% |
| 2002 FY | - USD | -77.13% |
| 2002 Q4 | -24.36 Million USD | -112.59% |
| 2002 Q2 | -10.79 Million USD | -473.81% |
| 2001 Q2 | -7.96 Million USD | -13.55% |
| 2001 Q4 | -10.06 Million USD | 44.26% |
| 2001 Q3 | -7.47 Million USD | 18.4% |
| 2001 Q1 | -6.54 Million USD | 13.1% |
| 2001 FY | - USD | -18.1% |
| 2000 Q2 | -5.49 Million USD | -478.86% |
| 2000 Q1 | -5.8 Million USD | 86.35% |
| 2000 Q3 | -6.34 Million USD | -19.97% |
| 2000 FY | - USD | 4.85% |
| 2000 Q4 | -8.02 Million USD | -21.08% |
| 1999 Q3 | -5.8 Million USD | -17.78% |
| 1999 Q2 | -4.88 Million USD | 76.44% |
| 1999 Q4 | -6.74 Million USD | -14.49% |
| 1999 FY | - USD | -51.72% |
| 1999 Q1 | -3.59 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 290.222% |
| Dynavax Technologies Corporation | 9.66 Million USD | -3110.056% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 363.735% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 102.751% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -215.772% |
| Perrigo Company plc | 646.2 Million USD | 51.983% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 216.649% |
| Illumina, Inc. | -608 Million USD | 151.034% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 97.127% |
| Nektar Therapeutics | -243.1 Million USD | 227.633% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 169.104% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 90.47% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 398.948% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 932.24% |
| Waters Corporation | 1.02 Billion USD | 69.647% |
| Biogen Inc. | 2.37 Billion USD | 86.946% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 454.906% |
| Adicet Bio, Inc. | -136.53 Million USD | 327.256% |
| Evolus, Inc. | -41.81 Million USD | 842.129% |
| bluebird bio, Inc. | -167.16 Million USD | 285.62% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 452.656% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 306.707% |
| FibroGen, Inc. | -261.4 Million USD | 218.699% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 81.498% |
| Homology Medicines, Inc. | -47.75 Million USD | 749.728% |
| Geron Corporation | -174.78 Million USD | 277.526% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 236.017% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 798.261% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 436.976% |
| Myriad Genetics, Inc. | -67.8 Million USD | 557.646% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 93.333% |
| OPKO Health, Inc. | -65.51 Million USD | 573.6% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 407.739% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 161.283% |
| Zoetis Inc. | 3.68 Billion USD | 91.58% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 713.549% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 73.344% |
| Exelixis, Inc. | 196.6 Million USD | -57.823% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 93.262% |
| uniQure N.V. | -253.1 Million USD | 222.593% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 959.941% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 656.503% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 237.91% |
| Verastem, Inc. | -83.16 Million USD | 473.09% |
| Imunon, Inc. | -20.78 Million USD | 1593.022% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 234.9% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 170.648% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 25.43% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -186.441% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 31.345% |
| TG Therapeutics, Inc. | 26.1 Million USD | -1088.828% |
| Blueprint Medicines Corporation | -474.61 Million USD | 165.376% |
| Insmed Incorporated | -654.73 Million USD | 147.39% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 189.816% |
| Incyte Corporation | 919.42 Million USD | 66.252% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 161.406% |